Post by PharmaShots

🚨 ESMO - European Society for Medical Oncology 𝗚𝗜 𝟮𝟬𝟮𝟲 delivered practice-changing insights across gastrointestinal cancers, and PharmaShots has distilled the biggest breakthroughs for you. From STRIDE + TACE emerging as a potential new standard in hepatocellular carcinoma to promising KRAS G12D-targeted therapies in pancreatic cancer, this year's meeting showcased the rapid evolution of precision oncology. 🔬 𝗞𝗲𝘆 𝗵𝗶𝗴𝗵𝗹𝗶𝗴𝗵𝘁𝘀 𝗶𝗻𝗰𝗹𝘂𝗱𝗲: ✅ Bristol Myers Squibb's KRYSTAL-10 final analysis in KRAS G12C metastatic colorectal cancer ✅ Arcus Biosciences & Gilead Sciences's STAR-221 Phase III update in gastric and gastroesophageal cancers ✅ Jazz Pharmaceuticals/BeOne Medicines' HERIZON-GEA-01 demonstrating improved survival while preserving quality of life ✅ AstraZeneca's EMERALD-3 and EMERALD-1 findings redefining immunotherapy strategies in HCC ✅ Revolution Medicines' encouraging early data for zoldonrasib in KRAS G12D-mutated pancreatic cancer ✅ Astellas Pharma's GLEAM study exploring biomarker-driven opportunities in CLDN18.2-positive pancreatic cancer Whether the data changed clinical practice or challenged existing treatment paradigms, 𝗘𝗦𝗠𝗢 𝗚𝗜 𝟮𝟬𝟮𝟲 reinforced the importance of precision medicine, biomarker-driven therapies, and innovative combination approaches in GI oncology. 📖 Explore all the key presentations, expert insights, and clinical takeaways with PharmaShots' comprehensive ESMO GI 2026 Key Highlights. 📩 Stay ahead of the latest breakthroughs in life sciences. Subscribe to the PharmaShots Weekly Newsletter and receive the most important industry updates, clinical trial results, regulatory news, and exclusive insights—delivered straight to your inbox every week. https://lnkd.in/gTU62Zbz #PharmaShots #ESMOGI2026 #ESMO #GastrointestinalCancer #Oncology #ClinicalTrials #PrecisionMedicine #Immunotherapy #TargetedTherapy #ColorectalCancer #PancreaticCancer #GastricCancer #LiverCancer #Biotech #Pharma #HealthcareInnovation #WeeklyNewsletter